Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

EN
Press Releases
Home  >  News  >  Press Releases
OBESITYWEEK® 2026 | HANSOH PHARMA PRESENTED PRECLINICAL CHARACTERIZATION OF HS-20136-2, A NOVEL ONCE-MONTHLY SUBCUTANEOUS GLP-1/GIP/GCG TRIPLE RECEPTOR AGONIST
Release Date:2026/11/16
Font Size

- HS-20136-2 features highly potent insulinotropic activity, unique GIPR biased signaling and robust preclinical anti-obesity efficacy.

- The ongoing clinical development of HS-20136-2 is progressing as planned. As a differentiated QM GLP-1R/GIPR/GCGR agonist, it has the potential to expand therapeutic options for patients.



SHANGHAI, November 16, 2026 — Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma"; 03692.HK) today announced that, in a Late-Breaking Abstract poster at ObesityWeek® 2026 (the 44th Annual Meeting of The Obesity Society, TOS), it presented results from preclinical studies of HS-20136-2, a novel once monthly subcutaneous glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP)/glucagon (GCG) Triple Receptor Agonist[1].

 

Details of the Poster Presentation Are as Follows:

Title: Discovery of HS-20136-2: A Novel Once Monthly Subcutaneous GLP-1/GIP/GCG Triple Receptor Agonist for the Treatment of Metabolic Disorders

Session: Gut Peptides, Appetite Signaling & Novel Therapeutics

Abstract No.: Poster-242

Date/Time: 11/14/2026, 7:30 pm - 8:30 pm  (EST)

Presenter: Ting Wang, Hansoh Pharma

 

Method:

This study employed a systematic evaluation framework spanning in vitro pharmacology, in vivo pharmacokinetics, and in vivo efficacy to comprehensively characterize the candidate's pharmacological profile.

 

Results:

• Receptor Agonism: HS-20136 showed slightly reduced cAMP potency at GLP-1R and GCGR but marginally enhanced activity at GIPR versus endogenous ligands under 0.1% casein conditions. In 100% human plasma, it was approximately 5-fold more potent than Retatrutide at GLP-1R and GCGR, with comparable potency at GIPR.

• Biased Agonism: HS-20136 exhibited a distinct GIPR signaling bias, with 60% lower β-arrestin-2 recruitment than Retatrutide, potentially reducing receptor desensitization and supporting sustained GIPR signaling.

• Glucose-Stimulated Insulin Secretion (GSIS): In human EndoC-βH5 cells, HS-20136 enhanced GSIS by 3.11-fold, with an EC₅₀ of 0.82 nM, exhibiting 3.3-fold higher GSIS potency than Retatrutide.

• In formulation development, HS-20136-2 employed Hansoh’s proprietary long-acting sustained-release technology to establish a subcutaneous drug depot, enabling gradual and sustained drug release. In non human primates,(NHP), HS-20136-2 can delay absorption rate and achieve steady drug release without burst release in one month, with Cmax/C672h ratio=1.8 after single subcutaneous dose of 0.5 mg/kg, supporting the once-monthly (QM) dosing regimen in clinical development.

• In DIO SD rats, a single administration of HS-20136-2 produced marked, sustained dose-dependent body weight loss, together with reduced food intake, demonstrating favorable preclinical anti-obesity efficacy.

 

These preclinical findings provide a pharmacological and pharmacokinetic rationale for the once-monthly subcutaneous regimen and for the exploration of clinical dosing regimens with longer intervals. If this dosing profile is confirmed in human studies, such regimens may reduce dosing frequency, enhance the convenience of long-term treatment, and improve patient adherence, offering a potential option for the long-term management of obesity and related metabolic disorders.

 

Based on the above preclinical findings, Hansoh Pharma has initiated Phase 1 clinical studies of HS-20136-2 in Australia and China to evaluate its safety and tolerability, as well as its pharmacokinetic (PK) and pharmacodynamic (PD) profiles in humans.

 

About HS-20136-2

HS-20136-2 is a novel unimolecular GLP-1R/GIPR/GCGR triagonist developed via Hansoh’s proprietary long-acting platform, designed to achieve coordinated activation of all three targets through a differentiated molecular design and receptor-signaling strategy. It demonstrates potent metabolic regulatory activity and robust insulinotropic effects, while its biased GIPR agonism may improve gastrointestinal tolerability. HS-20136-2 has demonstrated a favorable preclinical pharmacokinetic profile, supporting its potential for once-monthly subcutaneous administration and offering a potential new treatment option for patients with obesity, overweight, or hyperglycemia. Phase 1 clinical studies of HS-20136-2 have been initiated in China and Australia in participants with obesity or overweight to further evaluate its safety, tolerability, and pharmacokinetic profile.

 

About Obesity 

Obesity is a complex chronic disease driven by multiple factors. Currently, more than 650 million adults worldwide are affected, and the World Health Organization (WHO) has long recognized obesity as a major global public health epidemic requiring urgent action. According to data from 2025, the combined prevalence of overweight and obesity among adults in China has exceeded 50%[2] . As a major risk factor for a range of chronic conditions, obesity significantly increases the risk of type 2 diabetes, cardiovascular diseases and certain cancers, posing a substantial challenge to public health.

 

References:

1. Wang T, Sun DC, Yang XL, et al. Discovery of HS-20136-2: A Novel Once-Monthly Subcutaneous GLP-1/GIP/GCG Triple Receptor Agonist. Presented at: ObesityWeek®2026; Washington, DC. Poster 242.

2. World Obesity Federation. World Obesity Atlas 2025. Overweight, obesity and non-communicable diseases. New global, regional and national estimates of the prevalence of overweight and obesity in adults from 2000 to 2030. Mar, 2025. https://s3-eu-west-1.amazonaws.com/wof-files/World_Obesity_Atlas_2025_rev1.pdf




About Hansoh Pharma

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).

Statements

1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.


Forward-Looking Statements

This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).